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  Deteriorating environment condition, quick pace 
of  life,  improper  and  unbalanced  diet,  great  number  of 
stresses  and  pernicious  habits  lead  to  microflora 
imbalance. The  maximum  sensitivity to these effects is 
characteristic  of  microflora  of  intestine  which  reacts  to 
unfavorable  factors  long  before  appearance  of  clinical 
symptoms  by  reduction  of  indigenous  microflora  level 
and increase of quantity of opportunistic pathogens, that 
is, by condition of micloflora imbalance called dysbiosis 
[1,2]. 
Lately  dysbacterioses  of  various  etiologies  and 
degree of severity are rather frequent phenomena, in spite 
of  great  choice  of  medicinal  products  and  biologically 
active additives offered for their prevention. Among all 
products used for prevention and treatment of dysbiotic 
disorders, the medicinal products on the basis of bacteria 
typical  for  normal  microflora  of  healthy  people,  or 
probiotics, provide the widest range [3]. 
For rational development of new probiotics, it is 
necessary to take into consideration a quantitative ratio of 
different strains in intestine, their physiological features 
and  ability  to  survive  in  aggressive  conditions  (acid 
environment  in  stomach,  bile  acids),  to  provide  the 
maximum stay of bacteria in the appropriate loci in case 
of  taking  per  os  [4].  For  increase  of  effectiveness  of 
medicinal products, it is also rather important to choose 
correctly a prebiotic component for certain consortium. It 
is  necessary  to  indicate  that  the  prebiotic  component 
comprises not only an important supplement to probiotic 
medicinal products but also provides a source of feed for 
weakened representatives of patient’s intestine micloflora. 
We  proposed  a  medicinal  product  based  on 
consortium  of  bifidobacteria  belonging  to 
Bifidobacterium  bifidum  LVA-3  strain  and  lactobacilli 
belonging to Lactobacillus Plantarum strain with addition 
of lactitol as a prebiotic component [5]. 
Lactitol used as a prebiotic component is chosen 
for a number of reasons: lactitol is actively metabolized 
both by the pure cultures indicated above and in case of 
mutual cultivation of strains of the said bacteria. Besides, 
fatty acids  formed during lactitol fermentation by large 
intestine  microflora  have  no  influence  on  the  level  of 
glucose  and  insulin  in  blood,  so  composition  of  the 
probiotic  medicinal  product  proposed  by  us  may  be 
recommended for patient suffering from diabetes mellitus 
[6].  In  addition  to  this,  in  case  of  treatment  of  hepatic 
encephalopathy, cirrhosis and hepatitis, lactitol is able to 
change ratio of proteolytic and saccharolytic bacteria in 
favor of the latter, which leads to a considerable reduction 
of  endotoxins  level  in  patients  [7,8];  lactitol  has  no 
influence  on  bone  tissue  metabolism,  including 
concentration of parathormone, osteocalcin and alkaline 
phosphatase,  has  no  influence  on  concentration  of 
inorganic phosphate and calcium in blood plasma [9]. An 
important criterion that determined choice of lactitol as 
prebiotic  used  for  achievement  of  symbiotic  effect 
consists in that comparative study of influence of lactitol 
and lactulose on opportunistic pathogens and pathogens 
showed possibility of its selective action [10,11,12,13]. In 
particular, it is not split by coliform bacterium (E. coli) 
and  is  split  by  much  lesser  quantity  of  strains  of 
staphylococcus  (S.  aureus)  and  clostridium  (Cl. 
Perfringens) [9,14]. 
Work  objective  was  aimed  at  examination  and 
evaluation of safety of the proposed combined probiotic 
medicinal  product  on  the  basis  of  consortium  of 
Bifidobacterium bifidum LVA-3 strain and Lactobacillus 
Plantarum strain with addition of lactitol as a prebiotic 
component. 
 
Materials and methods 
To  assess  safety  of  the  developed  probiotic 
medicinal  product,  its  integral  action  on  the  body  was 
determined  according  to  the  requirements  of  Guiding 
document  РД  42-28-8-89  “Preclinical  testing  of  new 
immunobiological  medicinal  products.  Fundamental 
principles” by the following indices: 1) general toxicity; 
2) embryotoxicity; 3) general pharmacology [15]. 
The  preclinical  studies  were  conducted  on 
laboratory  mice  from  ICR  closed  colony,  males  and 
females, with mass of 18 to 20 g, age of 60 days, as well 
as on newborn mice. Husbandry: conventional, controlled 
by bacterial load parameters. The studies were conducted 
with  introduction  of  the  studied  medicinal  product  to 
animals per os in quantity corresponding to the dose of 
commercial  medicinal  products  intended  for  man.  The 
medicinal  product  was  given  to  experimental  animals 
once per day before feeding for 14 days. 
For obtaining the medicinal product, lyophilized 
Bifidobacterium bifidum LVA-3 strain was dissolved with 
Blaurock culture medium (pH 6.5±0.1) and cultivated at a 
temperature of (38±0.5)°C for 96 hours, by means of two 
successive  inoculations  having  48  hours  of  cultivation 
each.  Then  this  culture,  in  quantity  of  2.5%,  was 
introduced  into  modified  casein-yeast  KD-5  culture 
medium [16] prepared for cultivation. 
Lyophilized Lactobacillus Plantarum strain was 
dissolved with MRS-1 culture medium (pH 6.7±0.1) and 
cultivated at a temperature of (37±0.5)°C for 24 hours, 
then  subsequent  generations  were  obtained  on  media 
MRS-2  (pH  7.3±0.1)  and  MRS-4  (pH  7.9±0.1).  After 
taking the required quantity of stock culture of lactobacilli 
of the generation V, for further experiment, the culture 
was cultivated on MRS-1  medium (pH 6.7±0.1) for 24 
hours, to obtain the generation VI stock culture. Then the 
obtained  cultures  (7.5%  v/v)  were  introduced  into 
modified casein-yeast KD-5 culture medium prepared for 
cultivation. 
Mutual  cultivation  of  bifidobacteria  and 
lactobacillus (generations V and VI) was carried out on 50 
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modified  casein-yeast  KD-5  culture  medium  (pH 
7.0±0.1), with addition of lactitol in quantity of 1%, for 
24 hours at a temperature of (38±0.5)°C. 
To  determine  immunobiological  properties  of 
culture fluid, we examined sterile filtrate of culture fluid 
(SFCF)  of  Bifidobacterium  bifidum  LVA-3  strain 
bifidobacteria  and  Lactobacillus  Plantarum  strain 
lactobacilli  in  ratio  of  1:3.  The  filtrate  acidity  is 
(228±5)°T. 
The  immunopotentiating  activity  [17]  was 
studied on mice (12 in each group) by means of single 
subcutaneous introduction of adsorbed tetanus toxoid in a 
dose  of  0.2  ml  (2  binding  units)  manufactured  by  JSC 
“Biolek”.  The  sterile  filtrate  of  culture  fluid  was 
introduced to animals intraperitoneally or per os in a dose 
of 0.5 ml for 21 days. 0.9% solution of sodium chloride 
was introduced to control group of mice. After 21 days, 
we intraperitoneally introduced tetanus toxin in a dose of 
50  dlm  (dosis  letalis  minima)  and  observed  survival 
capability of the animals for 7 days. 
We studied antibacterial activity of the sterile filtrate of 
culture fluid. To determine antibacterial activity, we used 
Sh. Flexneri culture as a test strain in a dose of 200 mln. 
The  studies  were  conducted  along  two  lines:  we 
introduced to mice mixture of strains culture and sterile 
filtrate  of  culture  fluid  in  ratio  of  1:1  incubated  at 
(37±0.5)°C,  or  infected  the  animals  through 
intraperitoneal injection of 0.1 ml dose, with subsequent 
intraperitoneal  introduction  of  sterile  filtrate  of  culture 
fluid in a dose of 0.5 ml for 7 days. Only Sh. Flexneri 
culture was introduced to the control group. 
The safety of developed probiotic medicinal product was 
studied  in  parallel  with  that  of  commercially  available 
medicinal  products  “Bifidumbacterin”  and 
“Lactobacterin” manufactured by PrJSC “Biofarma”. 
 
Results and discussion 
While studying chronic toxicity of the medicinal 
product,  we  observed  its  stimulating  action  on  growth, 
development  and  survival  ability  of  the  animals.  The 
blood  hematological  parameters  were  within  normal 
physiological limits (Table 1). 
 
Table 1-Main hematological parameter characterizing blood of animals 
Hematological parameter characterizing blood of 
animals 
Results 
Intact animals  Experimental animals 
Red blood cells, mln/mm
3  5,80 ± 0,15  5,95 ± 0,26 
Leucocytes, thou./mm
3  5,24 ± 0,12  6,05 ± 0,12 
Hemoglobin, %  13,20 ± 0,13  14,6 ± 0,14 
 
Absence  of  changes  in  blood  hematological 
parameters and death of animals also testifies that strains 
included  in  composition  of  the  proposed  medicinal 
product are nonpathogenic. 
Histological  examination  of  target  organs 
(thymus, spleen, liver and duodenum) showed that there is 
no toxic action on these organs. The medicinal product 
showed  itself  as  immunologically  safe  not  having 
suppressive  action  on  quantitative  parameters  of 
circulating lymphocytes and hematogenesis function [18]. 
For example, absolute values of immune competent cells 
in experimental animals approached physiological normal 
values: quantity of lymphocytes was 2,70∙10
6 cells∙cm
-3, 
T- and B cells – 1,60∙10
6 cells∙cm
-3 and 1,18∙10
6 cells∙cm
-
3, respectively [19,20,21]. 
No immunotoxic action of the medicinal product 
on  lymphoid  system  organs  when  they  were  examined 
histologically was found: studies conducted on pregnant 
mouse  females  showed  total  absence  of  any 
embryotoxicity of the medicinal product. Besides, when it 
is  used,  a  considerable  improvement  of  organism 
condition  of  pregnant  female  animals,  reduction  of 
embryonic  mortality,  great  live  weight  gain  and  better 
survival  of  newborn  mice  are  observed;  the  conducted 
studies showed that there is no penetration bifidobacteria 
and lactobacilli into epithelial cells, no damaging action 
on  structure  of  intestinal  epithelium;  check  of 
effectiveness  of  physiological  action  of  the  medicinal 
product  on  mice  showed  a  stabilizing  influence  on 
functioning  gastrointestinal  tract,  fast  establishment  of 
microbiocenosis in mice; the conducted study on action of 
the medicinal product on condition of adult animals when 
they are kept at elevated temperatures testify of sustaining 
physiological  activity  of  experimental  mice,  which 
provides their survival in extreme conditions. 
The  obtained  results  testify  that  the  medicinal 
product  passed  the  tests  successfully.  As  a  whole,  the 
presented data give evidence of good prospects of further 
clinical study of the medicinal product and expediency of 
its use in combined therapy for the purpose of treatment 
and  prophylaxis.  Comparison  with  standard  medicinal 
products  shows  that  the  proposed  consortium  of 
bifidobacteria and lactobacilli does not differ by its safety 
from  commercially  available  medicinal  products 
“Bifidumbacterin” and “Lactobacterin” manufactured by 
PrJSC  “Biofarma”  but  simultaneously  provides  higher 
parameters of biological activity. 
Comparative analysis of the proposed medicinal 
product  and  commercially  available  standard  medicinal 
products is presented in Tables 2 and 3 [22]. 
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Table 2 -Main growth characteristics 
  Acid formation, °T  Survival capability 
On  Blaurock 
medium  after  48 
hours 
On MRS-1 medium 
after 24 hours 
On  Blaurock 
medium, GFU/ml 
On  MRS-1 
medium,  billion 
microbial cells 
Dry Bifidumbacterin  230,0 ± 5,0  -  10
9  - 
Dry Lactobacterin  -  220,0 ± 5,0  -  4,1 ± 0,2 
Complex preparation  392,0 ± 5,0  290,0 ± 5,0  10
12  6,4 ± 0,2 
 
 
 
Table 3 -Antagonistic activity of medicinal products (M ± m) 
Tested 
medicinal 
product 
Growth inhibition zone of test strains, mm 
Sh. 
Flexneri 
170 
Sh.  Sonnei 
5063 
Sh. 
Flexneri 
337 
E.coli 157  P. Vulgaris 
170 
P. Mirabilis  St. 
Aureus 
209 
Dry Bifidum-
bacterin 
 
18,80 ± 
0,27 
 
19,30 ± 
0,34 
 
18,60 ± 
0,44 
 
21,30 ± 
0,49 
 
19,8 ± 0,7 
 
17,60 ± 0,53 
 
- 
Dry Lacto-
bacterin 
25,30 ± 
0,41 
20,80 ± 
0,28 
22,7 ± 
0,42 
23,80 ± 
0,49 
21,60 ± 
0,27 
20,60 ± 0,37  21,80 ± 
0,29 
Complex 
preparation 
27,40 ± 
0,32 
22,5 ± 0,18  23,8 ± 
0,45 
23,90 ± 
0,35 
22,40 ± 
0,37 
21,90 ± 0,43  22,10 ± 
0,31 
 
Lately  a  great  interest  is  taken  in  creation  of 
medicinal products on the basis of acellular components 
of probiotic cultures. The culture fluid of these bacteria 
has  a  high  concentration  of  biologically  active 
components  including  bacteriocins,  proteases  and 
products of bacterial activity, which makes it possible to 
consider  culture  fluid  as  a  promising  material  for 
development  on  its  basis  of  medicinal  products  and 
biologically active additives. 
In the further group of experiments, we studied 
biological  activity  of  culture  fluids  not  containing 
microorganisms. 
While  studying  immunopotentiating  activity  of 
components  of  the  culture  fluid  obtained  during 
cultivation  of  tested  strains,  we  found  that  survival 
capability of control group of mice was 58%. In the group 
of  animals  which  obtained  the  sterile  filtrate  of  culture 
fluid, survival capability reached 75% for introduction per 
os and 83% for intraperitoneal injection. 
Study  of  immunopotentiating  activity  of  sterile 
filtrate  of  culture  fluid  showed  that  the  products  of 
bacterial  activity  in  case  of  introduction  to  animals 
immunized with vaccine enhance the immune response to 
antigen of sterile filtrate of culture fluid. 
Study  of  antibacterial  activity  showed  that  the 
products  accumulated  in  the  cultivation  media 
(bacteriocins, acids, adhesions, enzymes) may inactivate 
pathogenic  microflora,  protecting  organisms  of  infected 
animals from death both in vitro and in vivo. It was found 
that use of sterile filtrate of culture fluid leads to reduction 
of  death  rate  of  mice  both  in  case  of  incubation  with 
pathogenic  bacteria  and  introduction  to  animals.  In 
comparison  with  control  group,  the  death  rate  was 
reduced by 17-25% in case of preincubation and by 8-
17% in case of direct introduction to animals. 
At  present,  some  authors  propose  to  obtain 
concentrated and purified probiotic medicinal products. In 
our  opinion,  proceeding  from  obtained  data,  it  may  be 
concluded  that  reduction  of  quantity  of  bacterial 
metabolism products and all the more their removal from 
medicinal  product  is  unjustified  since  it  reduces 
immunobiological  activity  of  probiotic  medicinal 
products. 
 
Conclusions 
There  is  provided  an  optimized  process  of 
cultivation and obtaining an effective bacterial culture in 
laboratory  conditions  and  in  conditions  of  industrial 
production  and  developed  a  technology  of  mutual 
cultivation  of  bifidobacteria  of  Bifidobacterium  bifidum 
LVA-3 strain and lactobacilli of Lactobacillus Plantarum 
strain. The conducted studies made it possible to choose 
the optimum cultivation media and optimum balance of 
cultivated  strains,  as  well  as  to  study  the  main 
technological parameters. 
The  conducted  studies  demonstrated  a  high 
biological activity (acid formation, antagonistic activity, 
survival ability) of life functioning products of bacterial 
strains making part of the developed probiotic medicinal 
product. 
It  is  confirmed  that  it  is  possible  to  create  a 
medicinal  product  on  the  basis  of  biologically  active 
compounds  secreted  by  microorganisms  and  having 
immunopotentiating and antibacterial action. 
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The article treats issues of examination of safety of 
combined bacterial medicinal product on the basis of 
probiotic strains of bacteria belonging to two genera 
obtained by submerged mutual cultivation. During 
conducting experiments, it was found that the medicinal 
product causes no changes in blood hematological 
parameters of experimental animals, does not lead to their 
death, has no immunotoxic action, histological 
examination shows no deviations from the norm. In 
comparison with standard medicinal products, the 
proposed consortium of the said strains of bifidobacteria 
and lactobacilli does not differ by its safety from 
commercially available medicinal products 
“Bifidumbacterin” and “Lactobacterin” produced by 
PrJSC “Biofarma” but provides higher parameters of 
biological activity. 
There also was conducted examination of culture fluid 
activity after removal of proposed bacterial consortium. A 
high antibacterial activity of the sterile filtrate of culture 
fluid was found. 
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sterile filtrate of culture fluid, immunopotentiating 
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В статье рассмотрены вопросы изучения безопасности 
комбинированного бактериального препарата на 
основе пробиотических штаммов бактерий двух 
родов, выращенных совместным глубинным 
культивированием. В ходе проведенных 
экспериментов было установлено, что препарат не 
вызывает изменений в гематологических показаниях 
крови подопытных животных, не приводит к гибели 
животных, не имеет иммунотоксического 
воздействия, при гистологических исследованиях не 
обнаруживается отклонений от нормы. При 
сравнении со стандартными препаратами, 
предложенный консорциум указанных штаммов 
бифидобактерий и лактобацилл по своей 
безопасности не отличается от коммерческих 
препаратов ﾫБифидумбактеринﾻ и ﾫЛактобакеринﾻ 
производства ЧАО ﾫБиофармаﾻ, но дает более 
высокие показатели биологической активности. 
Также было проведено исследование активности 
культуральной жидкости, после удаления 
предлагаемого консорциума бактерий. Была 
установлена высокая иммуностимулирующая и 
антибактериальная активность стерильного фильтрата 
культуральной жидкости. 
Ключевые слова: пребиотический компонент, 
микрофлора, пробиотики, стерильный фильтрат 
культуральной жидкости, иммуностимулирующая 
активность, антибактериальная активность, 
безопасность. 
 
УДК 615.372 : 57.083.3 
ІММУНОБІОЛОГІЧНІ ВЛАСТИВОСТІ 
ПРЕПАРАТУ, ОТРИМАНОГО НА ОСНОВІ 
ШТАМІВ БІФІДОБАКТРІЙ ТА ЛАКТОБАЦИЛ 
Хижняк О.С. 
У статті розглянуто питання вивчення безпеки 
комбінованого бактеріального препарату на основі 
пробіотичних штамів бактерій двох родів, отриманих 
за допомогою сумісного глибинного культивування. В 
результаті проведених експериментів було 
встановлено, що препарат не викликає зміни 
гематологічних показників крові дослідних тварин, не 
приводить до загибелі тварин, не має 
іммунотоксичного впливу, при гістологічних дослідах 
не спостерігається відхилень від норми.  
При порівнянні зі стандартними препаратами, 
запропонований консорціум вказаних штамів 
біфідобактерій і лактобацил за рівнем безпеки не 
відрізняється від комерційних препаратів 
ﾫБіфідумбактеринﾻ та ﾫЛактобактеринﾻ виробництва 
ПАТ ﾫБіофармаﾻ, але дає значно вищі показники 
біологічної активності.  
Також було проведено дослідження активності 
культуральної рідини, після відділення 
запропонованого консорціуму бактерій. Була 
встановлена висока іммуностимулююча та 
антибактеріальна активність стерильного фільтрату 
культуральної рідини.   
Ключові слова: пребіотичний компонент, 
мікрофлора, пробіотики, стерильний фільтрат 
культуральної рідини, іммуностимулююча активність, 
антибактеріальна активність, безпечність. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 